Despite an improved revenue growth outlook, Indoco Remedies’ consensus price target has dropped notably as a declining future P/E signals reduced market confidence in the company's earnings quality, lowering fair value from ₹286.91 to ₹244.25.
What's in the News
- Indoco's UK subsidiary launched Ticagrelor film-coated tablets 90mg in the UK, to be marketed and distributed by Clarity Pharma.
- Received final USFDA approval for Allopurinol Tablets USP 200 mg; product will be manufactured in Goa, India.
- Board recommended a dividend of INR 0.20 per equity share for FY 2024-25, subject to shareholder approval.
- Board meeting held to approve audited financial results for quarter and year ended March 31, 2025, and recommend final dividend.
Valuation Changes
Summary of Valuation Changes for Indoco Remedies
- The Consensus Analyst Price Target has significantly fallen from ₹286.91 to ₹244.25.
- The Future P/E for Indoco Remedies has significantly fallen from 11.23x to 8.78x.
- The Consensus Revenue Growth forecasts for Indoco Remedies has risen from 12.8% per annum to 13.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.